Ebronucimab vs Evolocumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline

Ebronucimab

Marketed by Hubei Jumpcan Pharmaceutical and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT05255094 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. Its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Percentage change from baseline of serum LDL-C level (At week 12): LDL-C percentage change from baseline to week 12 vs placebo: 450 mg Q4W -59.13 percentage points (95% CI -64.10 to -54.15, adjusted p<0.0001); 150 mg Q2W -60.43 percentage points (95% CI -65.45 to -55.416, adjusted p<0.0001). (met)

Result source: NCT05255094

Evolocumab · Repatha

Marketed by Amgen

Approved in Atherosclerotic Cardiovascular Diseasemonoclonal antibody
Partial signal

NCT01516879 · Phase 3 · completed

The study randomly assigned 905 participants to quadruple-blinded monthly evolocumab or placebo, with both groups continuing background lipid-lowering therapy. The primary endpoint was met, with a statistically significant difference in LDL-C change at week 52, but LDL-C is a surrogate laboratory endpoint rather than a clinical outcome.

Next expected readout: November 2026 · NCT06496243 (registry estimate)

Reported efficacy

Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): Percent Change From Baseline to Week 24 in LDL-C (Baseline, Week 24): EvoMab 420 mg QM -44.53 percent change (Standard Error 2.17) vs Placebo -6.23 percent change (Standard Error 3.08) (met)

Result source: NCT02392559

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEbronucimabEvolocumab
LDL-C, % change—Not posted · NCT05260411-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496
Non-HDL-C, % change—Not posted · NCT05260411-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905
ApoB, % change—Not posted · NCT05260411-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905
Lp(a), % change—Not posted · NCT05260411-27.7% vs -5.4%−22.3 vs placebowk 52 · n 599NCT01516879
52 other results
  • -16.4% vs 10.3% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905
3-point MACE (% with event)—Not posted · NCT052604117.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633

LDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Evolocumab
-50.1% vs 6.8%−57 vs placebowk 52 · n 599NCT01516879
57 other results
  • -44.5% vs -6.2% 420 mg QM · wk 24 · n 104 · Phase 3 · primary NCT02392559
  • -55.2% vs 1.7% wk 24 · n 295 · Phase 3 · primary NCT02833844
  • -61.6% vs 8.1% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -58.2% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 8.1% Q2W · wk 12 · n 109 · Phase 3 · primary NCT01763866
  • -58.7% vs 8.1% QM · wk 12 · n 110 · Phase 3 · primary NCT01763866
  • -60.1% vs 8.1% Q2W · wk 12 · n 113 · Phase 3 · primary NCT01763866
  • -59.4% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -58.9% vs 8.1% Q2W · wk 12 · n 111 · Phase 3 · primary NCT01763866
  • -52.4% vs 8.1% QM · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -65.9% vs 8.1% Q2W · wk 12 · n 112 · Phase 3 · primary NCT01763866
  • -57.0% vs 8.1% QM · wk 12 · n 115 · Phase 3 · primary NCT01763866
  • -57.0% vs -1.3% Q2W · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -56.1% vs -1.3% QM · wk 12 · n 153 · Phase 3 · primary NCT01763827
  • -62.3% vs 7.1% QM · wk 12 · n 332 · Phase 3 · primary NCT02662569
  • -54.3% vs -1.1% wk 12 · n 280 · Phase 3 · primary NCT02739984
  • -69.0% vs 4.9% QM · n 332 · Phase 3 · primary NCT02662569
  • -61.3% vs 5.5% Q2W · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -55.7% vs 5.5% QM · wk 12 · n 110 · Phase 3 · primary NCT01763918
  • -64.7% vs 7.1% Q2W · wk 12 · n 325 · Phase 3 · primary NCT02662569
  • -73.6% vs 1.4% Q2W · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -64.6% vs 1.4% QM · wk 12 · n 50 · Phase 3 · primary NCT01953328
  • -74.5% vs 1.4% Q2W · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -70.4% vs 1.4% QM · wk 12 · n 51 · Phase 3 · primary NCT01953328
  • -73.7% vs -0.4% Q2W · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -70.0% vs -0.4% QM · wk 11 · n 50 · Phase 3 · primary NCT01953328
  • -74.8% vs -0.4% Q2W · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -76.9% vs -0.4% QM · wk 11 · n 51 · Phase 3 · primary NCT01953328
  • -61.4% vs 7.5% Q2W · n 110 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -61.8% vs 7.5% Q2W · n 109 · Phase 3 · primary NCT01763866
  • -65.0% vs 7.5% QM · n 110 · Phase 3 · primary NCT01763866
  • -59.3% vs 7.5% Q2W · n 113 · Phase 3 · primary NCT01763866
  • -63.8% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -59.1% vs 7.5% Q2W · n 111 · Phase 3 · primary NCT01763866
  • -62.9% vs 7.5% QM · n 112 · Phase 3 · primary NCT01763866
  • -66.2% vs 7.5% Q2W · n 112 · Phase 3 · primary NCT01763866
  • -62.5% vs 7.5% QM · n 115 · Phase 3 · primary NCT01763866
  • -56.9% vs -1.4% Q2W · n 153 · Phase 3 · primary NCT01763827
  • -58.8% vs -1.4% QM · n 153 · Phase 3 · primary NCT01763827
  • -61.2% vs 2.3% Q2W · n 110 · Phase 3 · primary NCT01763918
  • -63.3% vs 2.3% QM · n 110 · Phase 3 · primary NCT01763918
  • -65.3% vs 4.9% Q2W · n 325 · Phase 3 · primary NCT02662569
  • -65.0% vs -0.8% n 280 · Phase 3 · primary NCT02739984
  • -23.1% vs 7.9% wk 12 · n 33 · Phase 2/3 · primary NCT01588496
  • -52.8% vs -16.7% wk 24 · n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -18.1% Q2W · wk 12 · n 103 · Phase 3 · primary NCT01763905
  • -52.6% vs -18.1% QM · wk 12 · n 102 · Phase 3 · primary NCT01763905
  • -54.5% vs -16.7% n 145 · Phase 3 · primary NCT01984424
  • -56.1% vs -19.2% Q2W · n 103 · Phase 3 · primary NCT01763905
  • -55.3% vs -19.2% QM · n 102 · Phase 3 · primary NCT01763905
  • -54.4% vs 3.2% wk 12 · n 599 · Phase 3 · secondary NCT01516879
  • -59.0% vs 1.6% 420 mg QM · wk 16 · n 62 · Phase 3 · secondary NCT02729025
  • -48.0% vs -5.9% 420 mg QM · n 104 · Phase 3 · secondary NCT02392559
  • -57.8% vs -0.7% wk 7.14 · n 18 · Phase 3 · secondary NCT02189837
  • -83.2% vs -0.7% wk 7.14 · n 17 · Phase 3 · secondary NCT02189837
  • -25.6% vs 4.2% n 33 · Phase 2/3 · secondary NCT01588496

Non-HDL-C, % change

Ebronucimab
—Not posted · NCT05260411
Evolocumab
-41.8% vs 8.4%−50.3 vs placebowk 52 · n 599NCT01516879
50 other results
  • -41.2% vs -6.1% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -48.1% vs 2.9% wk 24 · n 296 · Phase 3 · secondary NCT02833844
  • -53.4% vs 7.9% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.2% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -54.8% vs 7.9% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -50.0% vs 7.9% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -52.0% vs 7.9% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -51.6% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -46.4% vs 7.9% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -59.0% vs 7.9% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -51.0% vs 7.9% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -50.1% vs 1.5% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 1.5% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -52.9% vs 5.9% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -59.1% vs 4.3% QM · n 332 · Phase 3 · secondary NCT02662569
  • -56.2% vs 5.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -49.7% vs 5.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -55.8% vs 5.9% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -46.9% vs -0.6% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -67.8% vs -0.1% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -58.0% vs -0.1% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -68.9% vs -0.1% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -63.3% vs -0.1% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -68.5% vs -1.6% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -61.7% vs -1.6% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -69.7% vs -1.6% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -69.1% vs -1.6% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -53.5% vs 7.0% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -56.1% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -54.4% vs 7.0% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -56.3% vs 7.0% QM · n 110 · Phase 3 · secondary NCT01763866
  • -52.6% vs 7.0% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -55.5% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -52.1% vs 7.0% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -55.7% vs 7.0% QM · n 112 · Phase 3 · secondary NCT01763866
  • -59.3% vs 7.0% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 7.0% QM · n 115 · Phase 3 · secondary NCT01763866
  • -50.2% vs 1.3% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -52.0% vs 1.3% QM · n 153 · Phase 3 · secondary NCT01763827
  • -55.8% vs 2.7% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -57.3% vs 2.7% QM · n 110 · Phase 3 · secondary NCT01763918
  • -56.6% vs 4.3% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -56.6% vs -0.1% n 280 · Phase 3 · secondary NCT02739984
  • -45.7% vs -14.6% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -48.6% vs -16.5% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -46.1% vs -16.5% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -47.4% vs -14.4% n 145 · Phase 3 · secondary NCT01984424
  • -48.7% vs -17.2% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -49.1% vs -17.2% QM · n 102 · Phase 3 · secondary NCT01763905

ApoB, % change

Ebronucimab
—Not posted · NCT05260411
Evolocumab
-41.3% vs 2.9%−44.2 vs placebowk 52 · n 599NCT01516879
53 other results
  • -34.9% vs -2.4% 420 mg QM · wk 24 · n 104 · Phase 3 · secondary NCT02392559
  • -45.1% vs 2.6% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -48.3% vs 3.3% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -50.9% vs 6.3% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -47.1% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 6.3% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -46.5% vs 6.3% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -50.1% vs 6.3% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -48.6% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -45.6% vs 6.3% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -43.7% vs 6.3% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -56.0% vs 6.3% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -49.2% vs 6.3% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -47.2% vs 1.8% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -46.6% vs 1.8% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -49.7% vs 3.2% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -56.4% vs 2.0% QM · n 332 · Phase 3 · secondary NCT02662569
  • -49.8% vs 4.6% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -44.8% vs 4.6% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -53.9% vs 3.2% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -40.3% vs 1.8% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -64.8% vs -2.5% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -54.8% vs -2.5% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -62.8% vs -2.5% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.4% vs -4.3% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -51.0% vs 5.1% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -51.4% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.1% vs 5.1% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -53.3% vs 5.1% QM · n 110 · Phase 3 · secondary NCT01763866
  • -49.8% vs 5.1% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -53.6% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.1% vs 5.1% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -53.0% vs 5.1% QM · n 112 · Phase 3 · secondary NCT01763866
  • -55.6% vs 5.1% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -54.4% vs 5.1% QM · n 115 · Phase 3 · secondary NCT01763866
  • -47.0% vs 1.5% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -49.4% vs 1.5% QM · n 153 · Phase 3 · secondary NCT01763827
  • -49.6% vs 2.2% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -52.8% vs 2.2% QM · n 110 · Phase 3 · secondary NCT01763918
  • -55.0% vs 2.0% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -50.2% vs 2.3% n 280 · Phase 3 · secondary NCT02739984
  • -19.2% vs 4.0% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -58.0% vs -2.5% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -64.8% vs -4.3% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -58.5% vs -4.3% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -64.2% vs -4.3% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -20.2% vs 2.6% n 33 · Phase 2/3 · secondary NCT01588496
  • -43.5% vs -11.7% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -45.8% vs -12.9% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -43.1% vs -12.9% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -45.3% vs -11.4% n 145 · Phase 3 · secondary NCT01984424
  • -45.9% vs -13.7% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -46.0% vs -13.7% QM · n 102 · Phase 3 · secondary NCT01763905

Lp(a), % change

Ebronucimab
—Not posted · NCT05260411
Evolocumab
-27.7% vs -5.4%−22.3 vs placebowk 52 · n 599NCT01516879
52 other results
  • -16.4% vs 10.3% wk 24 · n 302 · Phase 3 · secondary NCT02833844
  • -12.8% vs 1.1% 420 mg QM · wk 16 · n 63 · Phase 3 · secondary NCT02729025
  • -25.9% vs 11.4% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -20.3% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -24.6% vs 11.4% Q2W · wk 12 · n 109 · Phase 3 · secondary NCT01763866
  • -24.7% vs 11.4% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763866
  • -25.1% vs 11.4% Q2W · wk 12 · n 113 · Phase 3 · secondary NCT01763866
  • -20.9% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -26.1% vs 11.4% Q2W · wk 12 · n 111 · Phase 3 · secondary NCT01763866
  • -22.0% vs 11.4% QM · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -38.1% vs 11.4% Q2W · wk 12 · n 112 · Phase 3 · secondary NCT01763866
  • -29.2% vs 11.4% QM · wk 12 · n 115 · Phase 3 · secondary NCT01763866
  • -20.4% vs 0% Q2W · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -17.8% vs 0% QM · wk 12 · n 153 · Phase 3 · secondary NCT01763827
  • -25.2% vs 7.4% wk 12 · n 280 · Phase 3 · secondary NCT02739984
  • -42.3% vs 16.9% QM · n 332 · Phase 3 · secondary NCT02662569
  • -22.9% vs 6.7% Q2W · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -21.6% vs 6.7% QM · wk 12 · n 110 · Phase 3 · secondary NCT01763918
  • -35.9% vs 26.5% Q2W · wk 12 · n 325 · Phase 3 · secondary NCT02662569
  • -37.9% vs 26.5% QM · wk 12 · n 332 · Phase 3 · secondary NCT02662569
  • -45.7% vs 10.8% Q2W · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.7% vs 10.8% QM · wk 12 · n 50 · Phase 3 · secondary NCT01953328
  • -41.9% vs 10.8% Q2W · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.7% vs 10.8% QM · wk 12 · n 51 · Phase 3 · secondary NCT01953328
  • -45.0% vs 6.5% QM · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -49.5% vs 6.5% QM · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -26.0% vs 11.4% Q2W · n 110 · Phase 3 · secondary NCT01763866
  • -22.6% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.0% vs 11.4% Q2W · n 109 · Phase 3 · secondary NCT01763866
  • -27.5% vs 11.4% QM · n 110 · Phase 3 · secondary NCT01763866
  • -24.3% vs 11.4% Q2W · n 113 · Phase 3 · secondary NCT01763866
  • -23.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -25.0% vs 11.4% Q2W · n 111 · Phase 3 · secondary NCT01763866
  • -25.9% vs 11.4% QM · n 112 · Phase 3 · secondary NCT01763866
  • -38.6% vs 11.4% Q2W · n 112 · Phase 3 · secondary NCT01763866
  • -32.2% vs 11.4% QM · n 115 · Phase 3 · secondary NCT01763866
  • -18.4% vs 0% Q2W · n 153 · Phase 3 · secondary NCT01763827
  • -19.2% vs 0% QM · n 153 · Phase 3 · secondary NCT01763827
  • -24.0% vs 5.3% Q2W · n 110 · Phase 3 · secondary NCT01763918
  • -25.6% vs 5.3% QM · n 110 · Phase 3 · secondary NCT01763918
  • -38.6% vs 16.9% Q2W · n 325 · Phase 3 · secondary NCT02662569
  • -30.9% vs 9.6% n 280 · Phase 3 · secondary NCT02739984
  • -9.4% vs 2.4% wk 12 · n 33 · Phase 2/3 · secondary NCT01588496
  • -46.0% vs 6.5% Q2W · wk 11 · n 50 · Phase 3 · secondary NCT01953328
  • -43.0% vs 6.5% Q2W · wk 11 · n 51 · Phase 3 · secondary NCT01953328
  • -12.7% vs -1.4% n 33 · Phase 2/3 · secondary NCT01588496
  • -21.1% vs 0.2% wk 24 · n 145 · Phase 3 · secondary NCT01984424
  • -27.0% vs -1.7% Q2W · wk 12 · n 103 · Phase 3 · secondary NCT01763905
  • -22.1% vs -1.7% QM · wk 12 · n 102 · Phase 3 · secondary NCT01763905
  • -22.7% vs -1.6% n 145 · Phase 3 · secondary NCT01984424
  • -26.2% vs -2.3% Q2W · n 103 · Phase 3 · secondary NCT01763905
  • -23.7% vs -2.3% QM · n 102 · Phase 3 · secondary NCT01763905

3-point MACE (% with event)

Ebronucimab
—Not posted · NCT05260411
Evolocumab
7.9% vs 9.9%−2 vs placebowk 156 · n 13784NCT01764633
5 other results
  • 6.7% vs 8.3% wk 130 · n 13784 · Phase 3 · secondary NCT01764633
  • 5.5% vs 6.8% wk 104 · n 13784 · Phase 3 · secondary NCT01764633
  • 4.3% vs 5.2% wk 78 · n 13784 · Phase 3 · secondary NCT01764633
  • 3.1% vs 3.7% wk 52 · n 13784 · Phase 3 · secondary NCT01764633
  • 1.6% vs 1.9% wk 26 · n 13784 · Phase 3 · secondary NCT01764633
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Ebronucimab: 1 of 5 rows · Evolocumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEbronucimabEvolocumab
LDL-C
percent change · % of baseline
No placebo or comparator arm
-59.13% @ 12wk450 mg Q4Wa,b,c,d
NCT05255094 · Phase 3 · sponsor-reported, not registry data
show 1 more dose
-60.43% @ 12wk150 mg Q2W
NCT05255094 · Phase 3 · sponsor-reported, not registry data
-16.5% (n=8) @ 12wkb,c,d
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
4 other source trials
-18.26% (n=106) @ 12wk
NCT01624142 · Phase 2/3
-6.4% (n=29) @ 12wk
NCT03403374 · Phase 4 · registry result, not featured evidence
-64.5% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
-67.9% (n=82)
NCT01879319 · Phase 3 · registry result, not featured evidence
Dropout rate—
5.6%e
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
0%Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0.7%
NCT01764633 · Phase 3
3.2%
NCT02207634 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
7.3%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
5.4%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
10.5%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
1.7%QM
NCT01763866 · Phase 3
3.9%Q2W
NCT01763827 · Phase 3
1.3%QM
NCT01763827 · Phase 3
9%Q2W
NCT01763918 · Phase 3
1.8%QM
NCT01763918 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
30.2%
NCT01624142 · Phase 2/3
3%420 mg QM
NCT02624869 · Phase 3
2%420 mg QM
NCT02624869 · Phase 3
15.4%420 mg QM
NCT02624869 · Phase 3
38.3%
NCT04608474 · Phase 4 · registry result, not featured evidence
0%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
0%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
14.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
16.4%Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
3.7%
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
2.6%Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
1.5%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
3.2%
NCT02304484 · Phase 3 · registry result, not featured evidence
1.8%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
1.2%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
4.8%
NCT01984424 · Phase 3 · registry result, not featured evidence
0.7%
NCT02739984 · Phase 3 · registry result, not featured evidence
3.3%
NCT01813422 · Phase 3 · registry result, not featured evidence
13%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
9.5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
8.7%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
6.1%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
2.4%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
5.4%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
1.3%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
6.8%Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs—
—e
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—
NCT01764633 · Phase 3
—
NCT02207634 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763866 · Phase 3
—QM
NCT01763866 · Phase 3
—Q2W
NCT01763827 · Phase 3
—QM
NCT01763827 · Phase 3
—Q2W
NCT01763918 · Phase 3
—QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
—
NCT01624142 · Phase 2/3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
—420 mg QM
NCT02624869 · Phase 3
6.2%
NCT04608474 · Phase 4 · registry result, not featured evidence
—HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
—
NCT03403374 · Phase 4 · registry result, not featured evidence
—
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
—Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
—
NCT03570697 · Phase 3 · registry result, not featured evidence
—
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
—QM
NCT02634580 · Phase 3 · registry result, not featured evidence
—420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
—
NCT02304484 · Phase 3 · registry result, not featured evidence
—Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
—QM
NCT02662569 · Phase 3 · registry result, not featured evidence
—
NCT01984424 · Phase 3 · registry result, not featured evidence
—
NCT02739984 · Phase 3 · registry result, not featured evidence
—
NCT01813422 · Phase 3 · registry result, not featured evidence
—Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
—Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
—QM
NCT01953328 · Phase 3 · registry result, not featured evidence
—Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
—QM
NCT01763905 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
—Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
—Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
—All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
—All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
—SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Serious AEs—
5.5%e
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 64 more results
—Part A: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part A: OL Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
0%Part B: DB Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
—Part B: Evolocumab
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
24.8%
NCT01764633 · Phase 3
21.6%
NCT02207634 · Phase 3
3.6%Q2W
NCT01763866 · Phase 3
1.8%QM
NCT01763866 · Phase 3
2.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
0.9%Q2W
NCT01763866 · Phase 3
2.7%QM
NCT01763866 · Phase 3
2.7%Q2W
NCT01763866 · Phase 3
2.6%QM
NCT01763866 · Phase 3
1.8%Q2W
NCT01763866 · Phase 3
0.9%QM
NCT01763866 · Phase 3
2%Q2W
NCT01763827 · Phase 3
0.7%QM
NCT01763827 · Phase 3
2.7%Q2W
NCT01763918 · Phase 3
3.6%QM
NCT01763918 · Phase 3
—420 mg QM
NCT02392559 · Phase 3
1%420 mg QM
NCT02392559 · Phase 3
27.4%
NCT01624142 · Phase 2/3
2%420 mg QM
NCT02624869 · Phase 3
4.1%420 mg QM
NCT02624869 · Phase 3
16.7%420 mg QM
NCT02624869 · Phase 3
0%
NCT04608474 · Phase 4 · registry result, not featured evidence
5.3%HPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
4.5%NPR - Evolocumab
NCT03096288 · Phase 4 · registry result, not featured evidence
6.7%
NCT03403374 · Phase 4 · registry result, not featured evidence
0%
NCT03689946 · Phase 3 · registry result, not featured evidence
—Once Every 2 Weeks (Q2W) or Once a Month (QM)
NCT02867813 · Phase 3 · registry result, not featured evidence
41.8%Evolocumab in Parent Study
NCT02867813 · Phase 3 · registry result, not featured evidence
16.3%
NCT03570697 · Phase 3 · registry result, not featured evidence
3.3%
NCT02833844 · Phase 3 · registry result, not featured evidence
—Evolocumab + Standard of Care
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
7.9%Year 1: Evolocumab + Standard of C
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
14.4%Years 2-3: Evolocumab + SOC / Evol
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
15.1%Years 2-3: SOC / Evolocumab + SOC
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT02634580 · Phase 3 · registry result, not featured evidence
0%QM
NCT02634580 · Phase 3 · registry result, not featured evidence
3.1%420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
19.9%
NCT02304484 · Phase 3 · registry result, not featured evidence
3.1%Q2W
NCT02662569 · Phase 3 · registry result, not featured evidence
6.6%QM
NCT02662569 · Phase 3 · registry result, not featured evidence
6.2%
NCT01984424 · Phase 3 · registry result, not featured evidence
5%
NCT02739984 · Phase 3 · registry result, not featured evidence
27.9%
NCT01813422 · Phase 3 · registry result, not featured evidence
0%Evolocumab
NCT02189837 · Phase 3 · registry result, not featured evidence
5%Evolocumab and Atorvastatin
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
0%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
0%Q2W
NCT01953328 · Phase 3 · registry result, not featured evidence
2%QM
NCT01953328 · Phase 3 · registry result, not featured evidence
4.9%Q2W
NCT01763905 · Phase 3 · registry result, not featured evidence
1%QM
NCT01763905 · Phase 3 · registry result, not featured evidence
1.2%Evolocumab AI/Pen
NCT01879319 · Phase 3 · registry result, not featured evidence
0%Evolocumab AMD
NCT01879319 · Phase 3 · registry result, not featured evidence
2.7%Evolocumab AI/Pen
NCT01849497 · Phase 3 · registry result, not featured evidence
4%Evolocumab PFS
NCT01849497 · Phase 3 · registry result, not featured evidence
22%All-IP Period: Evolocumab + SOC /
NCT01439880 · Phase 2 · registry result, not featured evidence
19.6%All-IP Period: SOC / Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence
—Evolocumab + SOC
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
8.2%SOC-controlled Period: Evolocumab
NCT01439880 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs—
e
nasopharyngitis 10.5% (placebo 9.6%)
upper respiratory tract infection 9.3% (placebo 6.3%)
influenza 7.5% (placebo 6.3%)
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 54 more results
bronchitis 12.5% (placebo 0%)
dyspepsia 12.5% (placebo 0%)
pain 12.5% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
influenza 9.1% (placebo 0%)
upper respiratory tract infection 9.1% (placebo 6.3%)
gastroenteritis 6.1% (placebo 0%)
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
diabetes mellitus 8.4% (placebo 8%)
hypertension 7.8% (placebo 8.4%)
nasopharyngitis 7.7% (placebo 7.4%)
NCT01764633 · Phase 3
nasopharyngitis 10.3% (placebo 7.5%)
hypertension 6.2% (placebo 6.7%)
back pain 5.9% (placebo 3.6%)
NCT02207634 · Phase 3
Q2W
muscle spasms 2.7% (placebo 0%)
back pain 1.8% (placebo 0%)
diarrhoea 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
muscle spasms 3.6% (placebo 0%)
back pain 0.9% (placebo 0%)
dizziness 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
diarrhoea 3.7% (placebo 0%)
back pain 2.8% (placebo 0%)
muscle spasms 1.8% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
diarrhoea 1.8% (placebo 0%)
myalgia 1.8% (placebo 3.6%)
NCT01763866 · Phase 3
Q2W
back pain 1.8% (placebo 0%)
headache 1.8% (placebo 1.8%)
myalgia 0.9% (placebo 3.6%)
NCT01763866 · Phase 3
QM
headache 2.7% (placebo 1.8%)
back pain 0.9% (placebo 0%)
diarrhoea 0.9% (placebo 0%)
NCT01763866 · Phase 3
Q2W
muscle spasms 1.8% (placebo 0%)
back pain 0.9% (placebo 0%)
constipation 0.9% (placebo 5.4%)
NCT01763866 · Phase 3
QM
back pain 1.7% (placebo 0%)
diarrhoea 1.7% (placebo 0%)
dizziness 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
back pain 5.4% (placebo 0%)
dizziness 2.7% (placebo 0%)
muscle spasms 2.7% (placebo 0%)
NCT01763866 · Phase 3
QM
headache 4.3% (placebo 1.8%)
myalgia 2.6% (placebo 3.6%)
back pain 1.7% (placebo 0%)
NCT01763866 · Phase 3
Q2W
headache 3.3% (placebo 3.9%)
diarrhoea 2.6% (placebo 6.6%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
QM
diarrhoea 3.3% (placebo 6.6%)
headache 3.3% (placebo 3.9%)
nasopharyngitis 2% (placebo 1.3%)
NCT01763827 · Phase 3
Q2W
nasopharyngitis 7.3% (placebo 3.7%)
arthralgia 6.4% (placebo 1.9%)
headache 3.6% (placebo 1.9%)
NCT01763918 · Phase 3
QM
nasopharyngitis 10% (placebo 3.7%)
back pain 5.5% (placebo 0%)
headache 4.5% (placebo 1.9%)
NCT01763918 · Phase 3
420 mg QM
nasopharyngitis 11.5% (placebo 11.3%)
headache 10.6% (placebo 1.9%)
oropharyngeal pain 6.7% (placebo 0%)
NCT02392559 · Phase 3
upper respiratory tract infection 17%
headache 16%
influenza 16%
NCT01624142 · Phase 2/3
420 mg QM
nasopharyngitis 13.9%
headache 8.9%
influenza like illness 7.9%
NCT02624869 · Phase 3
420 mg QM
nasopharyngitis 16.3%
influenza like illness 10.2%
pyrexia 10.2%
NCT02624869 · Phase 3
420 mg QM
epistaxis 16.7%
abdominal pain upper 8.3%
acne 8.3%
NCT02624869 · Phase 3
allergic skin reaction 4.5%
elevated creatine kinase 1.5%
NCT04608474 · Phase 4 · registry result, not featured evidence
angina pectoris 3.3%
arthralgia 3.3%
arthritis 3.3%
NCT03403374 · Phase 4 · registry result, not featured evidence
runny nose 5.5%
NCT03689946 · Phase 3 · registry result, not featured evidence
hypertension 14.2% (placebo 12.9%)
bronchitis 6.9% (placebo 6.4%)
upper respiratory tract infection 6.5% (placebo 8.2%)
NCT02867813 · Phase 3 · registry result, not featured evidence
hypertension 7.5% (placebo 6.2%)
myalgia 6.3% (placebo 7.4%)
angina pectoris 5% (placebo 8.6%)
NCT03570697 · Phase 3 · registry result, not featured evidence
back pain 3.9% (placebo 2.5%)
influenza like illness 3.9% (placebo 2.5%)
diarrhoea 3.6% (placebo 4.5%)
NCT02833844 · Phase 3 · registry result, not featured evidence
nasopharyngitis 8.2%
arthralgia 4.3%
upper respiratory tract infection 4.2%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.6%
hypertension 7.5%
upper respiratory tract infection 7.4%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 12.6%
upper respiratory tract infection 8.3%
arthralgia 6.7%
NCT01854918 · Phase 3 · registry result, not featured evidence · combination
Q2W
pharyngitis 15.8%
abdominal distension 10.5%
abdominal pain 5.3%
NCT02634580 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 23.8%
hypertension 9.5%
injection site pain 9.5%
NCT02634580 · Phase 3 · registry result, not featured evidence
420 mg QM
influenza 10.8% (placebo 4.7%)
nasopharyngitis 9.2% (placebo 20.3%)
myalgia 7.7% (placebo 1.6%)
NCT02729025 · Phase 3 · registry result, not featured evidence
hypertension 6.4%
NCT02304484 · Phase 3 · registry result, not featured evidence
Q2W
diabetes mellitus 4.6% (placebo 1.2%)
nasopharyngitis 2.8% (placebo 3.7%)
upper respiratory tract infection 2.8% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
QM
diabetes mellitus 4.5% (placebo 1.2%)
upper respiratory tract infection 3.9% (placebo 3.7%)
nasopharyngitis 3.3% (placebo 3.7%)
NCT02662569 · Phase 3 · registry result, not featured evidence
myalgia 13.8%
nasopharyngitis 9.7%
arthralgia 9%
NCT01984424 · Phase 3 · registry result, not featured evidence
hypertension 3.9% (placebo 0%)
diabetes mellitus 2.9% (placebo 3.5%)
diarrhoea 2.1% (placebo 2.8%)
NCT02739984 · Phase 3 · registry result, not featured evidence
myalgia 7% (placebo 5.6%)
chest pain 6.8% (placebo 5.4%)
hypertension 6% (placebo 7%)
NCT01813422 · Phase 3 · registry result, not featured evidence
headache 36.4% (placebo 9.5%)
influenza like illness 9.1% (placebo 0%)
nasopharyngitis 9.1% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence
headache 35% (placebo 9.5%)
myalgia 10% (placebo 4.8%)
nausea 10% (placebo 4.8%)
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
Q2W
nasopharyngitis 13.7% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 0% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 15.7% (placebo 9.6%)
gastroenteritis 5.9% (placebo 1.9%)
diabetes mellitus 3.9% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
nasopharyngitis 24% (placebo 9.6%)
diabetes mellitus 2% (placebo 0%)
gastroenteritis 2% (placebo 1.9%)
NCT01953328 · Phase 3 · registry result, not featured evidence
QM
nasopharyngitis 14% (placebo 9.6%)
gastroenteritis 4% (placebo 1.9%)
diabetes mellitus 0% (placebo 0%)
NCT01953328 · Phase 3 · registry result, not featured evidence
Q2W
myalgia 6.8%
muscle spasms 4.9%
nasopharyngitis 4.9%
NCT01763905 · Phase 3 · registry result, not featured evidence
QM
headache 11.8%
pain in extremity 11.8%
myalgia 8.8%
NCT01763905 · Phase 3 · registry result, not featured evidence
headache 2.7%
NCT01849497 · Phase 3 · registry result, not featured evidence
headache 5.3%
NCT01849497 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.7%
upper respiratory tract infection 14.4%
back pain 14.2%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 30.7%
arthralgia 15.8%
upper respiratory tract infection 14.3%
NCT01439880 · Phase 2 · registry result, not featured evidence
nasopharyngitis 16.8%
upper respiratory tract infection 8.2%
back pain 7%
NCT01439880 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2/3 versus Phase 3.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for 60 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Evolocumab

LDL-C -44.53% (n=104) vs -6.23% (n=53) placebo @ 24wk420 mg QM
percent change · % of baseline
NCT02392559 · Phase 3
show 57 more results
-47.95% (n=104) vs -5.87% (n=53) placebo420 mg QM
NCT02392559 · Phase 3
-59.02% (n=62) vs 1.64% (n=59) placebo @ 16wk420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
-50.14% (n=599) vs 6.83% (n=302) placebo @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-54.35% (n=599) vs 3.17% (n=302) placebo @ 12wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-25.56% (n=33) vs 4.22% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-23.05% (n=33) vs 7.88% (n=16) placebo @ 12wk
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-61.56% (n=110) vs 9.86% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-58.19% (n=110) vs 9.86% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-61.8% (n=109) vs 9.86% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-58.68% (n=110) vs 9.86% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-60.09% (n=113) vs 9.86% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-59.4% (n=115) vs 9.86% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-58.89% (n=111) vs 9.86% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-52.4% (n=112) vs 9.86% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-65.86% (n=112) vs 9.86% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-57.02% (n=115) vs 9.86% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-61.41% (n=110) vs 8.54% (n=56) placeboQ2W
NCT01763866 · Phase 3
-62.47% (n=110) vs 8.54% (n=56) placeboQM
NCT01763866 · Phase 3
-61.8% (n=109) vs 8.54% (n=56) placeboQ2W
NCT01763866 · Phase 3
-65.05% (n=110) vs 8.54% (n=56) placeboQM
NCT01763866 · Phase 3
-59.33% (n=113) vs 8.54% (n=56) placeboQ2W
NCT01763866 · Phase 3
-63.79% (n=115) vs 8.54% (n=56) placeboQM
NCT01763866 · Phase 3
-59.08% (n=111) vs 8.54% (n=56) placeboQ2W
NCT01763866 · Phase 3
-62.94% (n=112) vs 8.54% (n=56) placeboQM
NCT01763866 · Phase 3
-66.17% (n=112) vs 8.54% (n=56) placeboQ2W
NCT01763866 · Phase 3
-62.45% (n=115) vs 8.54% (n=56) placeboQM
NCT01763866 · Phase 3
-57.04% (n=153) vs 0.1% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-56.12% (n=153) vs 0.1% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-56.93% (n=153) vs -0.43% (n=76) placeboQ2W
NCT01763827 · Phase 3
-58.81% (n=153) vs -0.43% (n=76) placeboQM
NCT01763827 · Phase 3
-61.25% (n=110) vs -2.02% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-55.74% (n=110) vs -2.02% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-61.23% (n=110) vs -1.08% (n=54) placeboQ2W
NCT01763918 · Phase 3
-63.25% (n=110) vs -1.08% (n=54) placeboQM
NCT01763918 · Phase 3
-55.23% (n=295) vs 1.68% (n=151) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-65.35% (n=325) vs 4.94% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-69.05% (n=332) vs 4.94% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-64.66% (n=325) vs 7.1% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-62.3% (n=332) vs 7.1% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-54.5% (n=145) vs -16.7% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-52.76% (n=145) vs -16.69% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-64.98% (n=280) vs -0.84% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-54.28% (n=280) vs -1.14% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-57.79% (n=18) vs -0.65% (n=19) placebo @ 7.14wk
NCT02189837 · Phase 3 · registry result, not featured evidence
-83.19% (n=17) vs -0.65% (n=19) placebo @ 7.14wk
NCT02189837 · Phase 3 · registry result, not featured evidence · combination
-73.7% (n=50) vs 0.27% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-69.98% (n=50) vs 0.27% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-74.82% (n=51) vs 0.27% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-76.93% (n=51) vs 0.27% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-73.57% (n=50) vs 1.28% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-64.62% (n=50) vs 1.28% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-74.46% (n=51) vs 1.28% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-70.36% (n=51) vs 1.28% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-56.14% (n=103) vs -18.08% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-52.6% (n=102) vs -18.08% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-56.11% (n=103) vs -19.21% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-55.31% (n=102) vs -19.21% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
LDL-C -77.5 vs -9 placebo mg/dL @ 24wk420 mg QM
absolute change · mg/dL
NCT02392559 · Phase 3
show 50 more results
-52.7 vs 5.1 placebo mg/dL @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-76.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-80.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-58.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-60.1 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-68.9 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-77.8 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-52.3 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-55.3 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-83.8 vs 6.8 placebo mg/dLQ2W
NCT01763866 · Phase 3
-78.4 vs 6.8 placebo mg/dLQM
NCT01763866 · Phase 3
-77 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-75.1 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-59 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-54.8 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-69.2 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-73.3 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-52.1 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-46.7 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-83.5 vs 8.6 placebo mg/dL @ 12wkQ2W
NCT01763866 · Phase 3
-72.5 vs 8.6 placebo mg/dL @ 12wkQM
NCT01763866 · Phase 3
-78.4 vs 1.2 placebo mg/dLQ2W
NCT01763827 · Phase 3
-81.9 vs 1.2 placebo mg/dLQM
NCT01763827 · Phase 3
-78.4 vs 1.9 placebo mg/dL @ 12wkQ2W
NCT01763827 · Phase 3
-77.9 vs 1.9 placebo mg/dL @ 12wkQM
NCT01763827 · Phase 3
-101.7 vs -6.5 placebo mg/dLQ2W
NCT01763918 · Phase 3
-98.8 vs -6.5 placebo mg/dLQM
NCT01763918 · Phase 3
-101.3 vs -8.5 placebo mg/dL @ 12wkQ2W
NCT01763918 · Phase 3
-87.2 vs -8.5 placebo mg/dL @ 12wkQM
NCT01763918 · Phase 3
-77.5 vs -2.3 placebo mg/dL @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-64.6 vs -2.1 placebo mg/dLQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-71.9 vs -2.1 placebo mg/dLQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-63.9 vs -0.3 placebo mg/dL @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-66.1 vs -0.3 placebo mg/dL @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-106.8 vs -31 Ezetimibe mg/dL
NCT01984424 · Phase 3 · registry result, not featured evidence
-102.9 vs -31.2 Ezetimibe mg/dL @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-75.5 vs -8.3 placebo mg/dL
NCT02739984 · Phase 3 · registry result, not featured evidence
-64.4 vs -8.6 placebo mg/dL @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-104.1 vs -14.8 placebo mg/dL @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-88.9 vs -14.8 placebo mg/dL @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-77.6 vs -14.8 placebo mg/dL @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-77.7 vs -14.8 placebo mg/dL @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-104.5 vs -13.7 placebo mg/dL @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-84 vs -13.7 placebo mg/dL @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-77.2 vs -13.7 placebo mg/dL @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-71.7 vs -13.7 placebo mg/dL @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-105.4 vs -39.1 Ezetimibe mg/dLQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-103.6 vs -39.1 Ezetimibe mg/dLQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-106 vs -36.2 Ezetimibe mg/dL @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-99 vs -36.2 Ezetimibe mg/dL @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
LDL-C 82.3% (n=599) vs 6.4% (n=302) placebo @ 52wk
responder rate · % of participants
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
Total Cholesterol -32.3% (n=599) vs 2.85% (n=302) placebo @ 12wk
percent change · % of baseline
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 18 more results
-28.18% (n=599) vs 5.26% (n=302) placebo @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-35.78% (n=296) vs 2.34% (n=152) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-38.64% (n=325) vs 2.89% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-39.74% (n=332) vs 2.89% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-37.82% (n=325) vs 4.4% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-35.22% (n=332) vs 4.4% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-38.04% (n=145) vs -11.43% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-36.64% (n=145) vs -11.57% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-42.19% (n=280) vs -1.13% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-34.97% (n=280) vs -1.23% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-48.03% (n=50) vs -2.49% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-42.34% (n=50) vs -2.49% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.19% (n=51) vs -2.49% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.49% (n=51) vs -2.49% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-47.14% (n=50) vs -1.7% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-39.06% (n=50) vs -1.7% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-44.04% (n=51) vs -1.7% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-40.88% (n=51) vs -1.7% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
Non-HDL-C -41.19% (n=104) vs -6.14% (n=53) placebo @ 24wk420 mg QM
percent change · % of baseline
NCT02392559 · Phase 3
show 50 more results
-41.82% (n=599) vs 8.44% (n=302) placebo @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-53.48% (n=110) vs 6.8% (n=56) placeboQ2W
NCT01763866 · Phase 3
-56.09% (n=110) vs 6.8% (n=56) placeboQM
NCT01763866 · Phase 3
-54.44% (n=109) vs 6.8% (n=56) placeboQ2W
NCT01763866 · Phase 3
-56.31% (n=110) vs 6.8% (n=56) placeboQM
NCT01763866 · Phase 3
-52.59% (n=113) vs 6.8% (n=56) placeboQ2W
NCT01763866 · Phase 3
-55.47% (n=115) vs 6.8% (n=56) placeboQM
NCT01763866 · Phase 3
-52.08% (n=111) vs 6.8% (n=56) placeboQ2W
NCT01763866 · Phase 3
-55.72% (n=112) vs 6.8% (n=56) placeboQM
NCT01763866 · Phase 3
-59.33% (n=112) vs 6.8% (n=56) placeboQ2W
NCT01763866 · Phase 3
-56.01% (n=115) vs 6.8% (n=56) placeboQM
NCT01763866 · Phase 3
-53.39% (n=110) vs 8.25% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-52.2% (n=110) vs 8.25% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-54.84% (n=109) vs 8.25% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-50.05% (n=110) vs 8.25% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-52.04% (n=113) vs 8.25% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-51.57% (n=115) vs 8.25% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-50.97% (n=111) vs 8.25% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-46.42% (n=112) vs 8.25% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-59.02% (n=112) vs 8.25% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-50.96% (n=115) vs 8.25% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-50.22% (n=153) vs -1.41% (n=76) placeboQ2W
NCT01763827 · Phase 3
-51.96% (n=153) vs -1.41% (n=76) placeboQM
NCT01763827 · Phase 3
-50.12% (n=153) vs -0.31% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-49.68% (n=153) vs -0.31% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-55.79% (n=110) vs 0.21% (n=54) placeboQ2W
NCT01763918 · Phase 3
-57.28% (n=110) vs 0.21% (n=54) placeboQM
NCT01763918 · Phase 3
-56.19% (n=110) vs -1.39% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-49.67% (n=110) vs -1.39% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-48.07% (n=296) vs 2.86% (n=152) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-56.57% (n=325) vs 4.33% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-59.08% (n=332) vs 4.33% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-55.76% (n=325) vs 5.87% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-52.92% (n=332) vs 5.87% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-47.44% (n=145) vs -14.38% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-45.72% (n=145) vs -14.62% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-56.62% (n=280) vs -0.05% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-46.89% (n=280) vs -0.6% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-68.48% (n=50) vs 0.18% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-61.69% (n=50) vs 0.18% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-69.72% (n=51) vs 0.18% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-69.07% (n=51) vs 0.18% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-67.81% (n=50) vs 1.12% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-58.03% (n=50) vs 1.12% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-68.89% (n=51) vs 1.12% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-63.27% (n=51) vs 1.12% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-48.72% (n=103) vs -17.18% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-49.13% (n=102) vs -17.18% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-48.62% (n=103) vs -16.53% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-46.15% (n=102) vs -16.53% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
Apo B -34.85% (n=104) vs -2.37% (n=53) placebo @ 24wk420 mg QM
percent change · % of baseline
NCT02392559 · Phase 3
show 53 more results
-48.3% (n=63) vs 3.29% (n=61) placebo @ 16wk420 mg QM
NCT02729025 · Phase 3 · registry result, not featured evidence
-41.26% (n=599) vs 2.94% (n=302) placebo @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-19.17% (n=33) vs 3.97% (n=16) placebo @ 12wk
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-20.24% (n=33) vs 2.65% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-50.95% (n=110) vs 7.55% (n=56) placeboQ2W
NCT01763866 · Phase 3
-51.44% (n=110) vs 7.55% (n=56) placeboQM
NCT01763866 · Phase 3
-49.14% (n=109) vs 7.55% (n=56) placeboQ2W
NCT01763866 · Phase 3
-53.26% (n=110) vs 7.55% (n=56) placeboQM
NCT01763866 · Phase 3
-49.79% (n=113) vs 7.55% (n=56) placeboQ2W
NCT01763866 · Phase 3
-53.59% (n=115) vs 7.55% (n=56) placeboQM
NCT01763866 · Phase 3
-47.07% (n=111) vs 7.55% (n=56) placeboQ2W
NCT01763866 · Phase 3
-52.95% (n=112) vs 7.55% (n=56) placeboQM
NCT01763866 · Phase 3
-55.65% (n=112) vs 7.55% (n=56) placeboQ2W
NCT01763866 · Phase 3
-54.37% (n=115) vs 7.55% (n=56) placeboQM
NCT01763866 · Phase 3
-50.9% (n=110) vs 7.89% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-47.15% (n=110) vs 7.89% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-49.77% (n=109) vs 7.89% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-46.47% (n=110) vs 7.89% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-50.15% (n=113) vs 7.89% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-48.58% (n=115) vs 7.89% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-45.61% (n=111) vs 7.89% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-43.71% (n=112) vs 7.89% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-55.95% (n=112) vs 7.89% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-49.16% (n=115) vs 7.89% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-47.04% (n=153) vs 0.05% (n=76) placeboQ2W
NCT01763827 · Phase 3
-49.39% (n=153) vs 0.05% (n=76) placeboQM
NCT01763827 · Phase 3
-47.21% (n=153) vs 0.59% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-46.59% (n=153) vs 0.59% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-49.58% (n=110) vs -0.19% (n=54) placeboQ2W
NCT01763918 · Phase 3
-52.76% (n=110) vs -0.19% (n=54) placeboQM
NCT01763918 · Phase 3
-49.75% (n=110) vs -0.67% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-44.81% (n=110) vs -0.67% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-45.14% (n=302) vs 2.59% (n=153) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-54.96% (n=325) vs 1.97% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-56.37% (n=332) vs 1.97% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-53.9% (n=325) vs 3.17% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-49.68% (n=332) vs 3.17% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-45.28% (n=145) vs -11.42% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-43.5% (n=145) vs -11.74% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-50.17% (n=280) vs 2.31% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-40.34% (n=280) vs 1.78% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-64.76% (n=50) vs -0.32% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-58.47% (n=50) vs -0.32% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-64.38% (n=51) vs -0.32% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-64.24% (n=51) vs -0.32% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-64.83% (n=50) vs 0.74% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-54.8% (n=50) vs 0.74% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-62.83% (n=51) vs 0.74% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-58.04% (n=51) vs 0.74% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.88% (n=103) vs -13.67% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-46.01% (n=102) vs -13.67% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-45.81% (n=103) vs -12.95% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-43.07% (n=102) vs -12.95% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
Lp(a -12.83% (n=63) vs 1.06% (n=61) placebo @ 16wk420 mg QM
percent change · % of baseline
NCT02729025 · Phase 3 · registry result, not featured evidence
show 52 more results
-27.72% (n=599) vs -5.37% (n=302) placebo @ 52wk
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
-9.4% (n=33) vs 2.43% (n=16) placebo @ 12wk
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-12.71% (n=33) vs -1.43% (n=16) placebo
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-26.01% (n=110) vs 6.07% (n=56) placeboQ2W
NCT01763866 · Phase 3
-22.64% (n=110) vs 6.07% (n=56) placeboQM
NCT01763866 · Phase 3
-23.97% (n=109) vs 6.07% (n=56) placeboQ2W
NCT01763866 · Phase 3
-27.46% (n=110) vs 6.07% (n=56) placeboQM
NCT01763866 · Phase 3
-24.26% (n=113) vs 6.07% (n=56) placeboQ2W
NCT01763866 · Phase 3
-23.16% (n=115) vs 6.07% (n=56) placeboQM
NCT01763866 · Phase 3
-24.96% (n=111) vs 6.07% (n=56) placeboQ2W
NCT01763866 · Phase 3
-25.93% (n=112) vs 6.07% (n=56) placeboQM
NCT01763866 · Phase 3
-38.64% (n=112) vs 6.07% (n=56) placeboQ2W
NCT01763866 · Phase 3
-32.16% (n=115) vs 6.07% (n=56) placeboQM
NCT01763866 · Phase 3
-25.87% (n=110) vs 7.34% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-20.25% (n=110) vs 7.34% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-24.61% (n=109) vs 7.34% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-24.68% (n=110) vs 7.34% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-25.09% (n=113) vs 7.34% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-20.85% (n=115) vs 7.34% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-26.11% (n=111) vs 7.34% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-21.97% (n=112) vs 7.34% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-38.06% (n=112) vs 7.34% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-29.23% (n=115) vs 7.34% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-18.37% (n=153) vs 0.12% (n=76) placeboQ2W
NCT01763827 · Phase 3
-19.24% (n=153) vs 0.12% (n=76) placeboQM
NCT01763827 · Phase 3
-20.41% (n=153) vs 0% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-17.82% (n=153) vs 0% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-24.03% (n=110) vs 7.34% (n=54) placeboQ2W
NCT01763918 · Phase 3
-25.65% (n=110) vs 7.34% (n=54) placeboQM
NCT01763918 · Phase 3
-22.89% (n=110) vs 8.68% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-21.55% (n=110) vs 8.68% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-16.44% (n=302) vs 10.35% (n=153) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-38.63% (n=325) vs 16.89% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-42.29% (n=332) vs 16.89% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-35.93% (n=325) vs 26.53% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-37.85% (n=332) vs 26.53% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-22.71% (n=145) vs -1.63% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-21.06% (n=145) vs 0.17% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-30.87% (n=280) vs 9.63% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-25.18% (n=280) vs 7.38% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-45.97% (n=50) vs 5.23% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.01% (n=50) vs 5.23% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-43.03% (n=51) vs 5.23% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-49.55% (n=51) vs 5.23% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.72% (n=50) vs 4.35% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-41.74% (n=50) vs 4.35% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-41.93% (n=51) vs 4.35% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-45.7% (n=51) vs 4.35% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-26.2% (n=103) vs -2.3% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-23.72% (n=102) vs -2.3% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-27.03% (n=103) vs -1.74% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-22.07% (n=102) vs -1.74% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
Triglycerides -2.55% (n=599) vs 8.99% (n=302) placebo @ 52wk
percent change · % of baseline
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 49 more results
-5.61% (n=110) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-13.38% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.27% (n=109) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.36% (n=110) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-10.28% (n=113) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.26% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-9.15% (n=111) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.43% (n=112) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-11.67% (n=112) vs 6.49% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.93% (n=115) vs 6.49% (n=56) placeboQM
NCT01763866 · Phase 3
-3.79% (n=110) vs 8.27% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-13.26% (n=110) vs 8.27% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-10.07% (n=109) vs 8.27% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-1.1% (n=110) vs 8.27% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-4.46% (n=113) vs 8.27% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-6.88% (n=115) vs 8.27% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-5.58% (n=111) vs 8.27% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-10.51% (n=112) vs 8.27% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-13.71% (n=112) vs 8.27% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-14.65% (n=115) vs 8.27% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-9.16% (n=153) vs -3.89% (n=76) placeboQ2W
NCT01763827 · Phase 3
-15.71% (n=153) vs -3.89% (n=76) placeboQM
NCT01763827 · Phase 3
-8.14% (n=153) vs -1.91% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-15.64% (n=153) vs -1.91% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-13.27% (n=110) vs 9.09% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.25% (n=110) vs 9.09% (n=54) placeboQM
NCT01763918 · Phase 3
-16.09% (n=110) vs 3.5% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-5.13% (n=110) vs 3.5% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-9.25% (n=296) vs 13.21% (n=152) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-6.48% (n=325) vs 11.54% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-7.15% (n=332) vs 11.54% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-5.91% (n=325) vs 10.5% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-4.24% (n=332) vs 10.5% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-5.39% (n=145) vs -0.95% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-2.88% (n=145) vs -1.07% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-12.64% (n=280) vs 6.61% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-8.9% (n=280) vs 4.81% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-23.23% (n=50) vs 4.69% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-17.41% (n=50) vs 4.69% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-22.12% (n=51) vs 4.69% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-12.66% (n=51) vs 4.69% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-19.73% (n=50) vs 7.84% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-15.63% (n=50) vs 7.84% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-21.05% (n=51) vs 7.84% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-9.63% (n=51) vs 7.84% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-6.32% (n=103) vs -3.74% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.73% (n=102) vs -3.74% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-3.88% (n=103) vs -5.47% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-2.53% (n=102) vs -5.47% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
HDL-C 5.77% (n=599) vs 0.35% (n=302) placebo @ 52wk
percent change · % of baseline
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 49 more results
5.54% (n=110) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.66% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
8.44% (n=109) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.76% (n=110) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
6.23% (n=113) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
7.72% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
4.86% (n=111) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.35% (n=112) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
10.35% (n=112) vs -0.99% (n=56) placeboQ2W
NCT01763866 · Phase 3
6.71% (n=115) vs -0.99% (n=56) placeboQM
NCT01763866 · Phase 3
7.04% (n=110) vs 0.22% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
7.88% (n=110) vs 0.22% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
9.09% (n=109) vs 0.22% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
7.36% (n=110) vs 0.22% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
6.07% (n=113) vs 0.22% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
7.18% (n=115) vs 0.22% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
4.65% (n=111) vs 0.22% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
5.57% (n=112) vs 0.22% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
10.92% (n=112) vs 0.22% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
6.41% (n=115) vs 0.22% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
3.89% (n=153) vs -1.64% (n=76) placeboQ2W
NCT01763827 · Phase 3
3.81% (n=153) vs -1.64% (n=76) placeboQM
NCT01763827 · Phase 3
4.76% (n=153) vs -1.15% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
4.06% (n=153) vs -1.15% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
7.93% (n=110) vs -0.45% (n=54) placeboQ2W
NCT01763918 · Phase 3
6.62% (n=110) vs -0.45% (n=54) placeboQM
NCT01763918 · Phase 3
8.05% (n=110) vs -1.15% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
5.35% (n=110) vs -1.15% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
11.08% (n=296) vs 2.73% (n=152) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
7.59% (n=325) vs 1.25% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
13.75% (n=332) vs 1.25% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
8.45% (n=325) vs 2.57% (n=164) placebo @ 12wkQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
14.18% (n=332) vs 2.57% (n=164) placebo @ 12wkQM
NCT02662569 · Phase 3 · registry result, not featured evidence
7.85% (n=145) vs 1.66% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
7.4% (n=145) vs 2.9% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
7.23% (n=280) vs -2.57% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
5.96% (n=280) vs -1.41% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
7.5% (n=50) vs -4.83% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
13.05% (n=50) vs -4.83% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
11.34% (n=51) vs -4.83% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
6.09% (n=51) vs -4.83% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
8.88% (n=50) vs -4.59% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
14.8% (n=50) vs -4.59% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
13.28% (n=51) vs -4.59% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
7.84% (n=51) vs -4.59% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
5.48% (n=103) vs 0.33% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
7.18% (n=102) vs 0.33% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
5.34% (n=103) vs 1.77% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
6.47% (n=102) vs 1.77% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
VLDL-C 2.74% (n=599) vs 31.89% (n=302) placebo @ 52wk
percent change · % of baseline
NCT01516879 · Phase 3 · combination · Atherosclerotic Cardiovascular Disease · phase 3
show 47 more results
-6.85% (n=110) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-11.77% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-8.96% (n=109) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-6.38% (n=110) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-12.22% (n=113) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-7.25% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-9.09% (n=111) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-15.05% (n=112) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-14.57% (n=112) vs 6.51% (n=56) placeboQ2W
NCT01763866 · Phase 3
-16.5% (n=115) vs 6.51% (n=56) placeboQM
NCT01763866 · Phase 3
-6.16% (n=110) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-11.73% (n=110) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-9.69% (n=109) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-1.06% (n=110) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-8.2% (n=113) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-6.28% (n=115) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-6.1% (n=111) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-9.95% (n=112) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-14.83% (n=112) vs 8.32% (n=56) placebo @ 12wkQ2W
NCT01763866 · Phase 3
-15.86% (n=115) vs 8.32% (n=56) placebo @ 12wkQM
NCT01763866 · Phase 3
-8.4% (n=153) vs -3.81% (n=76) placeboQ2W
NCT01763827 · Phase 3
-16.17% (n=153) vs -3.81% (n=76) placeboQM
NCT01763827 · Phase 3
-9.52% (n=153) vs -1.58% (n=76) placebo @ 12wkQ2W
NCT01763827 · Phase 3
-16.33% (n=153) vs -1.58% (n=76) placebo @ 12wkQM
NCT01763827 · Phase 3
-13.97% (n=110) vs 8.66% (n=54) placeboQ2W
NCT01763918 · Phase 3
-9.2% (n=110) vs 8.66% (n=54) placeboQM
NCT01763918 · Phase 3
-17.25% (n=110) vs 3.73% (n=54) placebo @ 12wkQ2W
NCT01763918 · Phase 3
-5.06% (n=110) vs 3.73% (n=54) placebo @ 12wkQM
NCT01763918 · Phase 3
-9.81% (n=284) vs 12.34% (n=141) placebo @ 24wk
NCT02833844 · Phase 3 · registry result, not featured evidence
-17.55% (n=325) vs 9.63% (n=164) placeboQ2W
NCT02662569 · Phase 3 · registry result, not featured evidence
-16.09% (n=332) vs 9.63% (n=164) placeboQM
NCT02662569 · Phase 3 · registry result, not featured evidence
-6.81% (n=145) vs -2.15% (n=73) Ezetimibe
NCT01984424 · Phase 3 · registry result, not featured evidence
-3.9% (n=145) vs -2.66% (n=73) Ezetimibe @ 24wk
NCT01984424 · Phase 3 · registry result, not featured evidence
-13.64% (n=280) vs 3.42% (n=141) placebo
NCT02739984 · Phase 3 · registry result, not featured evidence
-10.31% (n=280) vs 3.02% (n=141) placebo @ 12wk
NCT02739984 · Phase 3 · registry result, not featured evidence
-25.29% (n=50) vs 2.57% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-19.55% (n=50) vs 2.57% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-19.41% (n=51) vs 2.57% (n=49) placebo @ 11wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-17.2% (n=51) vs 2.57% (n=49) placebo @ 11wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-24.33% (n=50) vs 4.09% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-17.89% (n=50) vs 4.09% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-18.08% (n=51) vs 4.09% (n=49) placebo @ 12wkQ2W
NCT01953328 · Phase 3 · registry result, not featured evidence
-15.18% (n=51) vs 4.09% (n=49) placebo @ 12wkQM
NCT01953328 · Phase 3 · registry result, not featured evidence
-7.6% (n=103) vs -5.76% (n=51) EzetimibeQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.46% (n=102) vs -5.76% (n=51) EzetimibeQM
NCT01763905 · Phase 3 · registry result, not featured evidence
-6.16% (n=103) vs -5.49% (n=51) Ezetimibe @ 12wkQ2W
NCT01763905 · Phase 3 · registry result, not featured evidence
-2.18% (n=102) vs -5.49% (n=51) Ezetimibe @ 12wkQM
NCT01763905 · Phase 3 · registry result, not featured evidence
Non-HDL-C -32.37% (n=40) @ 80wk420 mg QM
percent change · % of baseline
No placebo or comparator arm
NCT02624869 · Phase 3
show 26 more results
-31.95% (n=88) @ 80wk420 mg QM
NCT02624869 · Phase 3
-13.03% (n=11) @ 80wk420 mg QM
NCT02624869 · Phase 3
-16.6% (n=8) @ 12wk
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-19.62% (n=106) @ 4wk
NCT01624142 · Phase 2/3
-18.17% (n=106) @ 6wk
NCT01624142 · Phase 2/3
-20.29% (n=106) @ 8wk
NCT01624142 · Phase 2/3
-17.05% (n=106) @ 12wk
NCT01624142 · Phase 2/3
-21.73% (n=106) @ 16wk
NCT01624142 · Phase 2/3
-24.09% (n=106) @ 20wk
NCT01624142 · Phase 2/3
-21.88% (n=106) @ 24wk
NCT01624142 · Phase 2/3
-22.43% (n=106) @ 36wk
NCT01624142 · Phase 2/3
-24.08% (n=106) @ 48wk
NCT01624142 · Phase 2/3
-24.81% (n=106) @ 60wk
NCT01624142 · Phase 2/3
-25.88% (n=106) @ 72wk
NCT01624142 · Phase 2/3
-21% (n=106) @ 84wk
NCT01624142 · Phase 2/3
-21.1% (n=106) @ 96wk
NCT01624142 · Phase 2/3
-24.17% (n=106) @ 108wk
NCT01624142 · Phase 2/3
-23.21% (n=106) @ 120wk
NCT01624142 · Phase 2/3
-26.39% (n=106) @ 132wk
NCT01624142 · Phase 2/3
-25.38% (n=106) @ 144wk
NCT01624142 · Phase 2/3
-22.35% (n=106) @ 156wk
NCT01624142 · Phase 2/3
-27.97% (n=106) @ 168wk
NCT01624142 · Phase 2/3
-26.32% (n=106) @ 180wk
NCT01624142 · Phase 2/3
-27.61% (n=106) @ 192wk
NCT01624142 · Phase 2/3
-27.22% (n=106) @ 204wk
NCT01624142 · Phase 2/3
-31.4% (n=106) @ 216wk
NCT01624142 · Phase 2/3
Apo B -27.1% (n=44) @ 80wk420 mg QM
percent change · % of baseline
No placebo or comparator arm
NCT02624869 · Phase 3
show 27 more results
-24.15% (n=87) @ 80wk420 mg QM
NCT02624869 · Phase 3
-19.17% (n=11) @ 80wk420 mg QM
NCT02624869 · Phase 3
-14.9% (n=8) @ 12wk
NCT01588496 · Phase 2/3 · monotherapy · Atherosclerotic Cardiovascular Disease, Homozygous Familial Hypercholesterolemia · phase 2/3
-16.91% (n=106) @ 4wk
NCT01624142 · Phase 2/3
-16.25% (n=106) @ 6wk
NCT01624142 · Phase 2/3
-17.57% (n=106) @ 8wk
NCT01624142 · Phase 2/3
-13.11% (n=106) @ 12wk
NCT01624142 · Phase 2/3
-18.65% (n=106) @ 16wk
NCT01624142 · Phase 2/3
-22.6% (n=106) @ 20wk
NCT01624142 · Phase 2/3
-20.09% (n=106) @ 24wk
NCT01624142 · Phase 2/3
-16.48% (n=106) @ 36wk
NCT01624142 · Phase 2/3
-15.9% (n=106) @ 48wk
NCT01624142 · Phase 2/3
-15.99% (n=106) @ 60wk
NCT01624142 · Phase 2/3
-20.7% (n=106) @ 72wk
NCT01624142 · Phase 2/3
-19.52% (n=106) @ 84wk
NCT01624142 · Phase 2/3
-15.07% (n=106) @ 96wk
NCT01624142 · Phase 2/3
-19.45% (n=106) @ 108wk
NCT01624142 · Phase 2/3
-21.58% (n=106) @ 120wk
NCT01624142 · Phase 2/3
-22.44% (n=106) @ 132wk
NCT01624142 · Phase 2/3
-21.24% (n=106) @ 144wk
NCT01624142 · Phase 2/3
-18.3% (n=106) @ 156wk
NCT01624142 · Phase 2/3
-20.38% (n=106) @ 168wk
NCT01624142 · Phase 2/3
-19.51% (n=106) @ 180wk
NCT01624142 · Phase 2/3
-19.38% (n=106) @ 192wk
NCT01624142 · Phase 2/3
-21.64% (n=106) @ 204wk
NCT01624142 · Phase 2/3
-22.68% (n=106) @ 216wk
NCT01624142 · Phase 2/3
-6% (n=29) @ 12wk
NCT03403374 · Phase 4 · registry result, not featured evidence

+ 36 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Evolocumab's landscape